Abstract:Abstract Introduction Sleep disruptions affect 56% of the population. Sleep disorders are common symptoms facing peri- and post-menopausal women. Ovariectomized rodents are a common study model for research on menopausal symptoms. The primary objective of this investigation was to evaluate the effects of BH_SLP_01 (Bonafide Health Sleep Product) on sleep quality and brain wave patterns in ovariectomized mice. Methods Five female BALB/c mice (age: 8 weeks, body mass: 180±20g) were allocated per treatment arm. After an adaptation period, all mice were ovariectomized (OVX). Treatment groups included caffeine control (control) and caffeine + BH_SLP_01. Both groups were treated with caffeine to induce sleep disturbance. Caffeine (7.5mg/kg) was injected intraperitoneally at the 15th minute of recordings, and second injections (saline or combinations) were performed at the 30th minute (min). Brain electrical activity was monitored and recorded for two hours total using electrocorticography (ECoG). Serum melatonin, serotonin, and dopamine were measured by ELISA. Brain levels of MDA were measured by HPLC and protein concentrations were determined using Western Blot analysis. Study treatments were compared using an ANOVA, Tukey’s post-hoc test, and Student's unpaired t-test. Significance levels were set at < 0.05. Results Analysis of ECoG recording data revealed notable findings. Significant differences in amplitude were seen at 15-30, 45-60, 60-75, and 75-90 min time points for the BL_SLP_01 group compared to control. Significant differences in frequency were seen at 15-30, 30-45, 45-60, 60-75, 75-90, and 90-105 min timepoints for the BH_SLP_01 group compared to control. Additionally, serotonin, dopamine, melatonin, brain MDA, GABA-A R2, GABA-B R1, GABA-B R2, 5-HT1A, GluA1, GluN1, GluN2A, Bax, Bcl-2, and Caspase-3 levels were significantly improved by BH_SLP_01 compared to control (p< 0.05). Conclusion This study provides evidence for the efficacy of BH_SLP_01 to improve impaired sleep in a menopausal model. This conclusion is supported by notable enhancements in sleep architecture demonstrated by ECoG recording data. Furthermore, the results show an upregulation of GABA, glutamine receptors, and natural melatonin, all of which collectively contribute to sleep quality. These findings underscore the potential of BH_SLP_01 as a promising therapeutic intervention for menopausal women experiencing sleep stress and disturbances. Support (if any) Research was supported by Bonafide Health, LLC.

Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder: a randomized crossover trial

Efficacy of Melatonin for Prolonged Disorders of Consciousness: a Double-Blind, Randomized Clinical Trial

Therapeutic sleep deprivation for major depressive disorder: A randomized controlled trial

Subacute changes in brain functional network connectivity after nocturnal sodium oxybate intake are associated with anterior cingulate GABA

Major depressive disorder with hypersomnolence complaint: A comparison study with non-depressed individuals examining objective biomarkers

0630 Efficacy of Sodium Oxybate in Adults with Idiopathic Hypersomnia : A Randomized Placebo-controlled Trial

Propofol enhancement of slow wave sleep to target the nexus of geriatric depression and cognitive dysfunction: protocol for a phase I open label trial

Improvement in sleep latency with extended-release once-nightly sodium oxybate for the treatment of adults with narcolepsy: Analysis from the phase 3 REST-ON clinical trial

Effect of trazodone versus cognitive‐behavioural treatment on high‐ and slow‐frequency activity during non‐rapid eye movement sleep in chronic insomnia: A pilot, randomized clinical trial

A group-based transdiagnostic sleep and circadian treatment for major depressive disorder: A randomized controlled trial.

Insomnia and the effect of zolpidem-extended-release on the sleep items of the Hamilton Rating Scale for Depression in outpatients with depression, insomnia, and suicidal ideation: Relationship to patient age

Baclofen and gamma-hydroxybutyrate differentially altered behavior, EEG activity and sleep in rats

Increased spindle density correlates with sleep continuity improvements following an eight‐week course of a melatonin agonist in people with depression: A proof‐of‐concept study with agomelatine

0226 A Novel GABAergic Dietary Supplement Enhances Sleep Quality in Ovariectomized Mice

Total Sleep Deprivation Followed by Bright Light Therapy as Rapid Relief for Depression: A Pragmatic Randomized Controlled Trial

Pharmacological advances in the treatment of insomnia

A Randomized, Double-Blind, Double-Dummy, Multicenter, Controlled Trial on Brotizolam Intervention in Outpatients with Insomnia

Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder

Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial

Effect of graduated drug therapy for moderate to severe chronic insomnia on the severity of disease: an observational study in Germany

Effective alleviation of depressive and anxious symptoms and sleep disorders in benzodiazepine-dependent patients through repetitive transcranial magnetic stimulation